Drug Trial Radar · NCT06173037
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jan 19, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
Conditions
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Epithelial Ovarian Cancer
Interventions
RC88Drug
2.0 mg/kg Q3W IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Up to approximately 2 years
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Xingtai People's Hospital
Xingtai, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shandong Cancer Hospital, Shandong Cancer Institute
Jinan, Shandong, China
Qingdao Central Hospital
Qingdao, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shangdong, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Second hospital of Shanxi Medical University
Taiyuan, Shanxi, China
The West China Second University Hospital of Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.